share_log

Repare Therapeutics Receives $1.5M Payment From Ono Pharmaceuticals

Repare Therapeutics Receives $1.5M Payment From Ono Pharmaceuticals

Repare Therapeutics 收到小野制药的 150 万美元
Benzinga Real-time News ·  2023/01/19 07:08

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. ("Ono"). The payment reflects achievement of a specified research trigger, under the companies' 2019 Strategic Partnership Agreement ("Ono Agreement"). Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan.

亚洲网加利福尼亚州圣何塞10月23日电临床阶段精确肿瘤学领先公司Repare治疗公司(以下简称Repare或公司)(纳斯达克代码:Rptx)今天宣布,该公司已从小野制药有限公司(以下简称小野制药)获得约150万美元(约合人民币2亿元)的研究服务金。这笔付款反映了根据两家公司的2019年战略合作伙伴协议(“小野协议”),完成了一项特定的研究触发因素。根据小野协议的条款,在美国或日本首次提交IND之前,REPARE主要负责其POLθ计划(现在称为RP-2119)的研究活动。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发